- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Atopic dermatitis
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 902KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 60KB)
Dupilumab – November 2020
Dupilumab (atopic dermatitis): Injection 200 mg in 1.14 mL single dose prefilled syringe, Injection 300 mg in 2 mL single dose prefilled syringe; Dupixent®
Last updated
19 March 2021